Human therapeutic agents

{
  "publication_number": "US10744124B2",
  "country": "US",
  "kind": "B2",
  "title": "Human therapeutic agents",
  "abstract": "Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.",
  "claims": [
    "1. A method of treating a cancer patient comprising the step of administering to the patient an anti-cancer composition comprising the combination of at least one curcumin component comprising curcumin, at least one harmine component comprising harmine, and at least one isovanillin component comprising isovanillin, wherein said composition exhibits anti-cancer synergy, wherein said cancer is selected from the group consisting of lymphoma, ovarian cancer and breast cancer.",
    "2. The method of claim 1, wherein said curcumin, said harmine, and said isovanillin are each at least about 50% pure.",
    "3. The method of claim 1, said isovanillin being present in an amount greater than the amounts of the harmine and the curcumin.",
    "4. The method of claim 1, the ratio of said at least one curcumin component, said at least one harmine component, and said at least one isovanillin component being from about 0.1-5:0.1-5:0.1-25.",
    "5. The method of claim 1, wherein the isovanillin component(s) is/are be present at a level of from about 25-85% by weight, the harmine component(s) is/are present at a level of from about 7-50% by weight, and the curcumin component(s) is/are present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.",
    "6. The method of claim 1, said composition exhibiting anti-cancer synergy with lymphoma cancer cells, MO205.",
    "7. The method of claim 1, said composition exhibiting anti-cancer synergy with ovarian cancer cells, A1847.",
    "8. The method of claim 1, said composition exhibiting anti-cancer synergy with breast cancer cells, du4475.",
    "9. The method of claim 1, wherein said components are individually and independently in the form of esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof.",
    "10. The method of claim 1, said composition being in the form of liquids, gels, suspensions, solutions, solids, capsules, pills, or tablets.",
    "11. The method of claim 1, including the step of administering said composition by oral, rectal, nasal, ophthalmic, parenteral, cutaneous, subcutaneous, or intramuscular administration.",
    "12. A method of inhibiting the growth of cancer cells comprising the step of contacting said cells with an anti-cancer composition comprising the combination of at least one curcumin component comprising curcumin, at least one harmine component comprising harmine, and at least one isovanillin component comprising isovanillin, wherein said composition exhibits anti-cancer synergy, wherein said cancer is selected from the group consisting of lymphoma, ovarian cancer and breast cancer.",
    "13. The method of claim 12, wherein said curcumin, said harmine, and said isovanillin are each at least about 50% pure.",
    "14. The method of claim 12, said isovanillin being present in an amount greater than the amounts of the harmine and the curcumin.",
    "15. The method of claim 12, the ratio of said at least one curcumin component, said at least one harmine component, and said at least one isovanillin component being from about 0.1-5:0.1-5:0.1-25.",
    "16. The method of claim 12, wherein the isovanillin component(s) is/are be present at a level of from about 25-85% by weight, the harmine component(s) is/are present at a level of from about 7-50% by weight, and the curcumin component(s) is/are present at a level of from about 5-40% by weight, based upon the total weight of the three components taken as 100% by weight.",
    "17. The method of claim 12, said composition exhibiting anti-cancer synergy with lymphoma cancer cells, MO205.",
    "18. The method of claim 12, said composition exhibiting anti-cancer synergy with ovarian cancer cells, A1847.",
    "19. The method of claim 12, said composition exhibiting anti-cancer synergy with breast cancer cells, du4475.",
    "20. The method of claim 12, wherein said components are individually and independently in the form of esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof."
  ],
  "description_excerpt": "The present invention relates to combination chemotherapeutics for treatment of humans, and especially for the treatment of human cancers, and corresponding methods for the treatment of humans suffering from cancers or other maladies. The invention further provides dosage forms and regimens for administration to human patients, and methods of formulating and administering such dosage forms to yield improvements in treatment outcomes. More particularly, the invention is concerned with the administration of specific chemotherapeutic dosage forms (e.g., liquid mixtures, capsules, pills, or tablets) containing one or more curcumin component(s), harmine component(s), and isovanillin component(s), and sub-combinations thereof.\n\nCancer is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumors and neoplasms. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs. This process is referred to as metastasis. Metastases are the major cause of death from cancer.\n\nThe transformation from a normal cell into a tumor cell is a multistage process, typically a progression from a pre-cancerous lesion to malignant tumors. These changes are the result of the interaction between a person's genetic factors and three categories of external agents, including:\n\nSome examples of infections associated with certain cancers:",
  "cpc": [
    "A61K 31/437",
    "A61K 31/11",
    "A61K 31/12",
    "A61K 31/4375",
    "A61K 45/06",
    "A61K 47/10"
  ],
  "ipc": [
    "A61K 31/11",
    "A61K 31/12",
    "A61K 31/437",
    "A61K 31/4375",
    "A61K 45/06",
    "A61K 47/10"
  ],
  "assignees": [
    "Ankh Life Sciences Ltd"
  ],
  "inventors": [
    "Gene H. Zaid",
    "Thomas W. Burgoyne"
  ],
  "filing_date": "2019-12-23",
  "publication_date": "2020-08-18",
  "grant_date": "2020-08-18",
  "priority_date": "2014-10-21",
  "application_number": "US-201916724935-A",
  "family_id": "57994722",
  "cited_by_count": 8,
  "citations": [
    "US10471049B2",
    "US10507200B1",
    "US10532043B2",
    "US10576067B2"
  ]
}